IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

23 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha

08 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

06 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Immutep to Participate in The JMP Securities Hematology and Oncology Summit

02 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

29 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Immutep Receives Australian R&D Tax Incentive

14 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

10 Nov 2022 10:10:00 By Nasdaq GlobeNewswire

Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022

10 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

09 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

04 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

02 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Immutep to Participate in Two Upcoming Investor Conferences

01 Nov 2022 18:59:04 By Nasdaq GlobeNewswire

Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

26 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

25 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

05 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer

04 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Immutep to Participate in Two Upcoming Investor Conferences

26 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Immutep Receives A$2.7 million R&D Tax Incentive from French Government

23 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

14 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board

13 Sep 2022 07:00:01 By Nasdaq GlobeNewswire